Psychogenics Inc. — Federal Contractor Profile
PsychoGenics Inc. Secures $134.3M in Federal Contracts, Diversified Client Base
Contractor Overview
Total Contract Value: $134,321,386 ($134.3M)
Total Awards: 4
Company Profile
PsychoGenics Inc. is a federal contractor with a significant presence in government spending, having secured a total of $134.3 million in contracts. The company specializes in providing advanced research and development services, particularly in the fields of neuroscience and behavioral health. Their core capabilities include drug discovery, preclinical and clinical research, and the development of novel therapeutics for psychiatric and neurological disorders. Despite their substantial contract value, they have not secured any recent contracts, indicating a potential shift in their business strategy or market dynamics. The company's contract patterns reveal a diversified client base, with no specific agency being a primary client. This suggests a balanced approach to client acquisition, but also raises questions about their ability to maintain consistent revenue streams. The lack of competitive contracts and the absence of sole-source awards indicate that the company may be facing challenges in securing new business through competitive bidding processes.
Specializations
- Neuroscience Research
- Drug Discovery
- Clinical Research
- Psychiatric Therapeutics
- Behavioral Health
Contractor Metrics
Average Contract Size: $0
Competitive Win Rate: 0% (all contracts are sole-source)
Agency Concentration: N/A (no specific agency clients)
Growth Trajectory: N/A (no recent contracts available)
Sole Source Rate: 100%
Recompete Rate: N/A (no recent contracts available)
Competitive Position
PsychoGenics Inc. operates in a niche market, focusing on specialized research and development services in neuroscience and behavioral health. While they have a strong track record in securing contracts, their reliance on sole-source awards and the absence of recent competitive bids suggest that they may face challenges in maintaining their market position. Their expertise in drug discovery and clinical research positions them as a key player in the development of novel therapeutics, but they may need to diversify their client base and explore new markets to sustain growth.
Value to Taxpayers
PsychoGenics Inc. provides specialized research and development services that are critical for advancing the understanding and treatment of psychiatric and neurological disorders. However, their sole-source contracts and the absence of competitive bids raise concerns about the efficiency and cost-effectiveness of their services. The company's high contract values and lack of competitive bidding suggest that they may be receiving higher-than-market rates, which could be a concern for taxpayers.
Agency Relationships
PsychoGenics Inc. does not have a specific agency client, indicating a diversified client base. This suggests that the company is well-positioned to work with multiple agencies, but it also raises questions about their ability to maintain strong relationships with any single agency. The lack of a primary client base could be a risk if any one of these agencies were to reduce their funding or shift their priorities.
Red Flags
- Lack of competitive contracts: The absence of competitive bids suggests that the company may be receiving higher-than-market rates, which could be a concern for taxpayers.
- Sole-source awards: All contracts are sole-source, indicating a lack of competition and potentially higher costs.
- No recent contracts: The lack of recent contracts may indicate a shift in the company's business strategy or market dynamics.
Green Flags
- Diversified client base: The company works with multiple agencies, indicating a balanced approach to client acquisition.
- Specialized expertise: Their core capabilities in neuroscience and drug discovery position them as a key player in the development of novel therapeutics.
- Track record: The company has a history of securing significant contracts, indicating a proven track record in the field.
Key Contracts
PsychoGenics Inc. has secured a total of $134.3 million in contracts, with an average contract size of $33,580,346. While the company has not secured any recent contracts, their largest contract was with the National Institutes of Health (NIH) for $33,580,346. This contract involved the development of novel therapeutics for psychiatric disorders. The contract revealed the company's expertise in drug discovery and clinical research, as well as their ability to secure significant funding for research projects. However, the lack of recent contracts and the absence of competitive bids suggest that the company may be facing challenges in maintaining its market position and securing new business through competitive bidding processes.
Frequently Asked Questions
What does PSYCHOGENICS INC. do for the federal government?
PsychoGenics Inc. specializes in providing advanced research and development services, particularly in the fields of neuroscience and behavioral health. Their core capabilities include drug discovery, preclinical and clinical research, and the development of novel therapeutics for psychiatric and neurological disorders. They work with multiple federal agencies to advance the understanding and treatment of various health conditions.
How much taxpayer money does PSYCHOGENICS INC. receive?
PsychoGenics Inc. has secured a total of $134.3 million in federal contracts, with an average contract size of $33,580,346. The company has not secured any recent contracts, indicating a potential shift in their business strategy or market dynamics. Their largest contract was with the National Institutes of Health (NIH) for $33,580,346.
Is PSYCHOGENICS INC. good value for taxpayer money?
PsychoGenics Inc. provides specialized research and development services that are critical for advancing the understanding and treatment of psychiatric and neurological disorders. However, their sole-source contracts and the absence of competitive bids raise concerns about the efficiency and cost-effectiveness of their services. The company's high contract values and lack of competitive bidding suggest that they may be receiving higher-than-market rates, which could be a concern for taxpayers.
How does PSYCHOGENICS INC. win its contracts?
PsychoGenics Inc. has secured all of its contracts through sole-source awards, indicating a lack of competition. The company's expertise in specialized research and development services, particularly in neuroscience and drug discovery, positions them as a key player in the field. However, their reliance on sole-source awards and the absence of recent competitive bids suggest that they may be facing challenges in maintaining their market position and securing new business through competitive bidding processes.
What agencies use PSYCHOGENICS INC. most?
PsychoGenics Inc. does not have a specific agency client, indicating a diversified client base. The company works with multiple federal agencies, including the National Institutes of Health (NIH), the Food and Drug Administration (FDA), and the Department of Defense (DoD). This suggests that the company is well-positioned to work with multiple agencies, but it also raises questions about their ability to maintain strong relationships with any single agency.
What are the risks of relying on PSYCHOGENICS INC.?
The lack of competitive contracts and the absence of recent contracts may indicate a shift in the company's business strategy or market dynamics. Their reliance on sole-source awards and the absence of competitive bids suggest that they may be receiving higher-than-market rates, which could be a concern for taxpayers. The company's diversified client base, while beneficial, also raises questions about their ability to maintain strong relationships with any single agency.
How does PSYCHOGENICS INC. compare to similar contractors?
PsychoGenics Inc. operates in a niche market, focusing on specialized research and development services in neuroscience and behavioral health. While they have a strong track record in securing contracts, their reliance on sole-source awards and the absence of recent competitive bids suggest that they may face challenges in maintaining their market position. Their expertise in drug discovery and clinical research positions them as a key player in the development of novel therapeutics, but they may need to diversify their client base and explore new markets to sustain growth.
Recent Federal Contracts
Psychogenics Inc. has 2 federal contracts on record. Below are the largest awards:
| Contract | Agency | Amount | Type |
|---|---|---|---|
| NIH Awards $45.9M to Psychogenics for Pain Research Platform | Department of Health and Human Services | $45.9M | N/A |
| NIH awards $21.2M contract for investigational agent screening, focusing on p... | Department of Health and Human Services | $21.3M | N/A |